US Medical Second Opinion Market Report Scope & Overview:

The US Medical Second Opinion Market size was valued at USD 2.65 Billion in 2025 and is expected to reach USD 10.29 Billion by 2035, at 14.52% CAGR from 2026 to 2035

The US Medical Second Opinion Market is expanding as large employer-sponsored benefit programs and a dense concentration of leading academic medical centers continue reinforcing the country's position as the largest national second-opinion market tracked in this report. Growing insurer willingness to commission independent specialist review for high-cost oncology and cardiac procedures is sustaining nationwide demand, while mature telehealth infrastructure continues removing geographic barriers that once limited specialist access outside major metropolitan clusters.

Leading domestic second-opinion providers continue expanding specialist-matching technology to handle rising referral volumes without proportionally growing physician headcount, and growing collaboration between health systems and dedicated vendors is further strengthening nationwide service capacity. Rising federal attention to healthcare-cost transparency is reinforcing demand for independent specialist confirmation, and state-level benefit mandates across several states are competing to expand access, even as skilled-subspecialist availability remains a constraint in several clinical fields.

⮞In March 2026, Cedars-Sinai expanded its Virtual Second Opinion program to residents in 39 U.S. states, with access to more than 150 specialists reviewing over 600 conditions. The announcement demonstrates nationwide growth in remote expert medical review beyond established local specialist-referral networks.

Global Medical Second Opinion Market Size

The Global Medical Second Opinion Market was valued at USD 8.36 Billion in 2025 and is projected to reach USD 34.57 Billion by 2035, registering a CAGR of 15.30% from 2026 to 2035, driven primarily by rising employer-sponsored benefit adoption and growing insurer use of independent specialist review.

North America Medical Second Opinion Market Size

The North America Medical Second Opinion Market was valued at USD 3.22 Billion in 2025 and is projected to reach USD 12.62 Billion by 2035, registering a CAGR of 14.64% from 2026 to 2035, driven by sustained oncology and cardiac review volumes and growing insurer utilization-management demand across the United States and Canada.

By Type, Hospital Physicians/Specialties Dominates the US Medical Second Opinion Market and Medical Second Opinion Companies Grows Fastest

Hospital Physicians/Specialties retained the largest type share in the United States, reflecting the country's dense concentration of named-physician second-opinion programs tied to oncology, cardiology and neurology service lines at leading academic medical centers. Large domestic hospital systems continue using these programs as a retention tool for complex-case patients who might otherwise be referred to an outside third-party network. Deep institutional reputation nationwide further reinforces this channel's entrenched procurement advantage, particularly for rare or high-acuity diagnoses requiring narrow subspecialty expertise.

Medical Second Opinion Companies are forecast to grow fastest as dedicated U.S. platforms increasingly compete with hospital-affiliated channels for employer and insurer contracts nationwide. Domestic employers increasingly favor these vendors for standardized turnaround times and documentation across a national specialist panel rather than relying on a single named institution. Growing venture investment in U.S. second-opinion-focused health-technology platforms is further accelerating specialist-matching capability nationwide. Expanding case-management software and AI-assisted triage tools are additionally lowering the per-case cost of operating a large, nationwide specialist panel, widening the pool of vendors able to compete for sizeable employer and insurer contracts across every U.S. region.

⮞In June 2026, Genomate Health launched a physician-led, AI-supported cancer second-opinion service in the United States, initially available in 11 states. Its remote model combines tumor genomic analysis with independent oncologist review to help patients evaluate evidence-based treatment alternatives.

By Source of Service, In-House Dominates the US Medical Second Opinion Market and Outsourced Grows Fastest

In-House second-opinion review dominated the United States as large hospital systems and integrated health networks continue routing requests to employed specialists rather than external panels. Keeping review in-house allows these systems to retain the referral and associated treatment revenue, a strong incentive reinforced by established electronic health record integration nationwide. Workforce expertise accumulated at existing academic centers further discourages a shift toward external review pathways for core, high-volume specialties across the country.

Outsourced second-opinion review is forecast to grow fastest as smaller U.S. hospital systems and employers increasingly rely on external specialist networks rather than building comparable in-house capability. Domestic employers without access to a large academic medical center of their own are increasingly contracting dedicated vendors for comparable specialist access. Growing insurer willingness nationwide to commission outsourced review for high-cost cases is further reinforcing this channel's above-average growth trajectory. Rising use of dual-sourcing arrangements, where insurers contract more than one vendor to manage surge volumes, is further widening the addressable market for outsourced providers nationwide, particularly among employers seeking faster turnaround than a single in-house program can reliably deliver.

⮞In December 2025, Transcarent announced that it was adding independent expert second opinions to all major surgery requests through its 2nd.MD service. The revised approach pairs external specialist review with a cap on surgery care-coordination fees, reinforcing employers’ use of outsourced clinical validation before procedures.

By Application, Cancer Dominates the US Medical Second Opinion Market and Neurological Disorders Grows Fastest

Cancer applications dominated U.S. demand, reflecting the high stakes and treatment variation associated with an oncology diagnosis nationwide. Patients and families remain especially motivated to confirm a diagnosis and treatment plan before proceeding with surgery, chemotherapy or radiation, reinforcing oncology's position as the largest single application segment tracked in this report. Growing availability of molecular and genomic testing nationwide is further increasing the complexity of oncology cases referred for specialist review.

Neurological Disorders applications are forecast to grow fastest as rising diagnosis rates for complex conditions such as epilepsy and movement disorders increasingly prompt U.S. patients to seek subspecialist confirmation. Growing availability of neurology subspecialists on dedicated second-opinion platforms is widening nationwide patient access to review previously limited to a handful of academic centers. Expanding insurer coverage for neurological second-opinion review is further reinforcing this application's above-average growth trajectory nationwide. Growing use of advanced neuroimaging and genetic-testing data in referral packets is further increasing the clinical complexity of neurological cases routed for specialist confirmation across the country, particularly among patients referred from smaller regional health systems lacking an in-house neurology subspecialist.

⮞February 2026: Sun Life U.S. expanded Expert Cancer Review by introducing proactive outreach when eligible members filed cancer-related disability or supplemental health claims. The program connects members with independent oncology specialists and reported that 41% of facilitated opinions in 2024–2025 affected diagnoses, diagnostic strategies or treatment plans.

Regional Analysis

Northeast US Medical Second Opinion Market Insights

The Northeast dominated the US Medical Second Opinion Market with the largest sub-regional revenue share of approximately 34.50% in 2025, supported by New Jersey's and New York's dense concentration of originator academic medical centers and established specialist-referral infrastructure built up over decades. Proximity to major teaching hospitals and regulatory affairs talent continues reinforcing the Northeast's leadership position relative to newer technology-enabled clusters elsewhere in the country, particularly for complex oncology and neurological cases.

New Jersey and New York accounted for the largest share of Northeast revenue, anchored by multiple leading academic medical center headquarters and specialist-referral networks, while Pennsylvania contributed additional demand through established hospital-affiliated second-opinion programs. Continued institutional investment in named-physician review programs should keep the Northeast's leadership position intact through the forecast period, reinforced by decades of accumulated specialist depth. Dense regional clustering of teaching hospitals and research universities further supports faster subspecialist recruitment relative to lower-density sub-regions elsewhere in the country, and ongoing state-level life-sciences incentive programs in New Jersey and New York are further encouraging institutions to expand rather than relocate existing specialist-referral infrastructure.

⮞In May 2025, Cambridge, Massachusetts-based Genomate Health announced its formal entry into the U.S. market alongside an additional USD 2 million in funding. The investment supported the expansion of its computational precision-oncology tools and planned U.S. clinical partnerships; the announcement did not constitute a second-opinion service launch.

West US Medical Second Opinion Market Insights

The West is anticipated to witness the highest growth rate at a CAGR of about 16.80% from 2026-2035, owing to California's strong health-technology ecosystem and rising demand for technology-enabled second-opinion platforms among employers that do not rely on a single named academic institution. Greater venture-capital access for West Coast health-technology companies is helping support above-average growth for specialist-matching platforms originating from the region. Expanding university-affiliated incubator programs across the region are additionally feeding a steady pipeline of new health-technology sponsors seeking early specialist-network partnerships, further reinforcing the West's above-average growth trajectory relative to more established Northeast institutions.

California accounted for the largest share of West Coast revenue, anchored by a dense concentration of health-technology companies and employer-benefit partnerships, while Washington contributed additional demand through specialty telehealth second-opinion capacity. Growing collaboration between West Coast employers and technology-enabled second-opinion vendors is expected to reinforce this above-average growth trajectory through the forecast period. Continued state-level support for digital-health infrastructure in California is further reinforcing the region's attractiveness for new specialist-matching platform investment and employer-benefit partnership activity.

⮞In May 2025, Cedars-Sinai published a California patient case showing how its Virtual Second Opinion service enabled a specialist spine review without an initial trip to Los Angeles. The case illustrates established remote access for complex orthopaedic treatment decisions, rather than a newly launched West Coast service.

Midwest and South US Medical Second Opinion Market Insights

The Midwest accounted for a meaningful share of U.S. revenue, buoyed by Illinois' established hospital-affiliated specialist-referral base and proximity to large academic medical center operations. Indiana and Ohio were also able to leverage a deep regional pool of clinical specialists and lower operating costs than coastal clusters to provide additional demand through outsourced second-opinion capacity serving regional employer customers. The strong concentration of employer headquarters across the Midwest further supports steady demand for standardized, employer-sponsored second-opinion benefit programs.

The South contributed a growing share of national revenue, led by North Carolina's expanding health-system and biomanufacturing-adjacent specialist cluster, with Texas also beginning to attract new employer-benefit second-opinion investment. Continued state-level benefit-mandate discussions across both regions are expected to support further demand growth through the forecast period, as more employers evaluate lower-cost alternatives to coastal specialist-review vendors for new benefit-program investment. Growing availability of telehealth-licensed subspecialists near Research Triangle-area universities is further reinforcing the South's appeal for new capacity investment, and expanding regional biomanufacturing employment is additionally widening the pool of employers evaluating dedicated second-opinion benefit programs for their workforces.

⮞In August 2026, Cleveland Clinic published an updated account of its Virtual Second Opinions workflow, describing how dedicated nurse intake, clinical-record collection and subspecialist review can support patients and their referring physicians. This was a service explanation, not an announced expansion in the Midwest or South.

Market Dynamics

Growth Drivers: Employer-Benefit Expansion and Sustained Oncology and Cardiac Demand

The U.S. industry is driven by growing employer-sponsored second-opinion benefit adoption, sustained oncology, cardiac and neurological review volumes nationwide, and rising insurer interest in independent specialist review as a utilization-management tool. As health systems and payers prioritize both cost containment and improved treatment accuracy, demand for domestic second-opinion capacity continues rising nationwide.

Growing AI-enabled case triage, reinforced by Teladoc Health's and Cleveland Clinic's platform expansions, is reinforcing this driver by giving providers flexible access to larger referral volumes without proportional headcount growth. Expanding collaboration between health systems and dedicated second-opinion vendors is further widening the addressable client base across the country.

⮞In June 2025, Sun Life U.S. launched Expert Cancer Review for new and renewing medical stop-loss policies effective July, enabling eligible employees with cancer diagnoses to obtain independent, documented oncology second opinions. The launch provides a concrete example of employer-sponsored insurance benefits incorporating specialist review.

Restraints: State Licensing Complexity and Reimbursement Variability

Licensing fragmentation across U.S. states continues restraining faster capacity expansion, as physicians providing remote second-opinion review must often hold licensure in the patient's home state, complicating efforts to scale a single specialist network nationwide. Limited availability of highly specialized subspecialists, particularly in rare-disease and complex oncology fields, further constrains how quickly providers can expand case-handling capacity without compromising review quality.

Reimbursement variability across U.S. payers also complicates capacity expansion decisions, as insurance coverage for second-opinion services differs considerably by state and plan type. Because new specialist-credentialing cycles can take considerable time, some providers continue favoring partnerships with existing credentialed networks over building entirely new physician panels nationwide.

Opportunities: Technology-Enabled Specialist Matching and State Benefit Mandates

Growing state-level benefit-mandate discussions represent a significant opportunity across the United States, as several states evaluate formal second-opinion access requirements within employer health plans. Providers positioned early in states adopting such mandates stand to capture meaningful share as nationwide coverage continues broadening beyond voluntary employer adoption.

Expansion of AI-enabled case triage and specialist-matching technology offers a second opportunity for domestic providers able to differentiate on turnaround speed rather than network size alone. Continued collaboration between insurers and dedicated second-opinion vendors is expected to further accelerate this opportunity through the remainder of the forecast period.

US Medical Second Opinion Market Companies are:

• Teladoc Health

• Included Health

• 2nd.MD

• Cleveland Clinic

• Mayo Clinic

• Johns Hopkins Medicine International

• Cigna Healthcare

• Optum

• HCA Healthcare

• MDLIVE

• WorldCare International

• AXA Health

• PinnacleCare International

• Alight Solutions

• MORE Health

• Sun Life Health Navigator

• Accolade

• Medisense Healthcare Solutions

• Global Second Opinion

• Second Opinion International

US Medical Second Opinion Market Report Scope: